靶向T-ALL/T-LBL中细胞因子及治疗诱导的PIM1激活
本研究在CD127+ T-ALL/T-LBL临床前模型中揭示,内源性IL7可上调致癌激酶PIM1,使肿瘤对PIM抑制敏感;短期化疗后残留肿瘤细胞PIM1一过性上调,部分由糖皮质激素转录上调IL7RA介导;化疗联合pan-PIM抑制剂可改善PDX模型生存。
要点
- IL7通过CD127上调T-ALL/T-LBL中PIM1表达,增强对PIM抑制的敏感性。
- 短期化疗后残留CD127+肿瘤细胞PIM1一过性上调,糖皮质激素上调IL7RA参与介导。
- 化疗联合pan-PIM抑制剂在CD127+ T-ALL PDX模型中改善生存。
核心结论
- IL7与糖皮质激素协同驱动CD127+ T-ALL/T-LBL中PIM1异常激活,提示诱导化疗期间联合PIM抑制可能获益。
研究设计与样本
- 临床前研究,使用CD127+ T-ALL/T-LBL细胞及多种异种移植模型(含PDX),评估IL7、化疗和PIM抑制的效果。
主要发现
- 内源性IL7可增加CD127+ T-ALL/T-LBL中PIM1表达,使肿瘤细胞在体内对PIM抑制敏感。
- 短期体内化疗后残留肿瘤细胞较未治疗 bulk 肿瘤细胞PIM1一致上调,该效应在化疗中止后重建疾病中未观察到,呈一过性。
- 糖皮质激素可转录上调PDX细胞中IL7RA,至少部分介导内源性IL7引起的非细胞自主性PIM1上调。
- 在CD127+ T-ALL PDX模型中,化疗联合pan-PIM抑制剂改善白血病生存。
临床怎么用
- 对IL7反应性CD127+ T-ALL/T-LBL患者,诱导化疗期间可考虑联合PIM抑制策略(基于临床前证据)。
局限性
- 证据来自临床前模型,尚未在患者中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that are currently treated with high-dose chemotherapy. Over the last several years, the search toward novel and less-toxic therapeutic strategies for T-ALL/T-LBL patients has largely focused on the identification of cell-intrinsic properties of the tumor cell. However, non-cell-autonomous activation of specific oncogenic pathways might also offer opportunities that could be exploited at the therapeutic level. In line with this, we here show that endogenous interleukin 7 (IL7) can increase the expression of the oncogenic kinase proviral integration site for Moloney-murine leukemia 1 (PIM1) in CD127+ T-ALL/T-LBL, thereby rendering these tumor cells sensitive to in vivo PIM inhibition. In addition, using different CD127+ T-ALL/T-LBL xenograft models, we also reveal that residual tumor cells, which remain present after short-term in vivo chemotherapy, display consistent upregulation of PIM1 as compared with bulk nontreated tumor cells. Notably, this effect was transient as increased PIM1 levels were not observed in reestablished disease after abrogation of the initial chemotherapy. Furthermore, we uncover that this phenomenon is, at least in part, mediated by the ability of glucocorticoids to cause transcriptional upregulation of IL7RA in T-ALL/T-LBL patient-derived xenograft (PDX) cells, ultimately resulting in non-cell-autonomous PIM1 upregulation by endogenous IL7. Finally, we confirm in vivo that chemotherapy in combination with a pan-PIM inhibitor can improve leukemia survival in a PDX model of CD127+ T-ALL. Altogether, our work reveals that IL7 and glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that IL7-responsive CD127+ T-ALL and T-LBL patients could benefit from PIM inhibition during induction chemotherapy.
引用
- De Smedt R, Morscio J, Reunes L, et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020. PMID: 32315407. doi:10.1182/blood.2019003880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。